EyePoint Settles False Claims Act Case, Accepts Five-Year Compliance Agreement
Regulatory Oversight
Company Background
EyePoint, Inc. (Nasdaq: EYPT) — renamed from EyePoint Pharmaceuticals in December 2025 — is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on sustained-delivery treatments for serious retinal diseases. Its lead candidate, DURAVYU™ (vorolanib intravitreal insert), is in two Phase 3 programs: LUGANO and LUCIA for wet age-related macular degeneration, with topline data expected beginning mid-2026, and COMO and CAPRI for diabetic macular edema, which dosed first patients in March 2026 and are targeting topline data in the fourth quarter of 2027.
The company's commercial legacy has been winding down. Total net revenue fell from $43.3 million in 2024 to $31.4 million in 2025, and reached just $0.7 million in the first quarter of 2026 — down from $24.5 million in the same period a year earlier — as deferred revenue from the 2023 license of YUTIQ® product rights was fully recognized. The net loss widened to $232 million for full-year 2025 and $84.8 million in the first quarter of 2026. Cash, cash equivalents, and marketable securities stood at $223 million as of March 31, 2026, with management guiding that amount as sufficient to fund operations into the fourth quarter of 2027.
DEXYCU®, the product at the center of the settled claims, was commercialized by EyePoint from 2019 to 2023. The company no longer markets it.
What Was Disclosed
A settlement agreement dated July 17, 2026 resolves potential civil liability under the False Claims Act, the Civil Monetary Penalties Law, and the Administrative False Claims Act arising from EyePoint's sales, marketing, promotional, and sampling practices for DEXYCU® during its commercial life from 2019 to 2023. The counterparties are the United States, acting through the DOJ and on behalf of OIG-HHS and the Defense Health Agency (which oversees the TRICARE military health program), and a named relator — a whistleblower who had filed the underlying civil action. EyePoint agreed to pay $4,678,981.86 plus interest accruing at 4.25% per annum from January 28, 2026: $4,657,463.18 (plus interest) flows to the federal government and $21,518.68 (plus interest) to certain participating states, both due within 14 days of the July 17 effective date. An additional $166,500 covers the relator's attorneys' fees and costs, due within 60 days. EyePoint stated it intends to use cash on hand for all payments. The settlement does not constitute an admission of liability, and upon payment the DOJ, OIG-HHS, DHA, and the relator have agreed to release EyePoint from civil and administrative monetary liability arising from the covered conduct and to dismiss the relator's civil action.
Separately, a Corporate Integrity Agreement with OIG-HHS took effect July 13, 2026 — four days before the settlement — and runs for five years. Its obligations include maintaining a Compliance Officer and Compliance Committee, subjecting compliance matters to board review and oversight, retaining a board-level compliance expert, providing management certifications, conducting compliance training, establishing written policies and procedures aligned with federal healthcare program requirements, engaging an independent review organization, screening employees to confirm they are not barred from federal healthcare programs, and implementing a risk assessment and internal review process. In exchange, OIG-HHS agreed not to seek EyePoint's exclusion from Medicare, Medicaid, or other federal healthcare programs as a result of the covered conduct. Failure to meet CIA obligations could trigger monetary penalties or program exclusion.
Why It Matters
The investigation behind this settlement was not a surprise: EyePoint had listed the August 2022 subpoena from the U.S. Attorney's Office for the District of Massachusetts as a risk factor in multiple subsequent filings, and the May 2026 first-quarter earnings press release explicitly named the goal of reaching a settlement agreement and corporate integrity agreement as a known risk and operational priority. In that sense, the settlement closes a chapter that has shadowed the company's compliance profile for nearly four years. The payment itself — roughly $4.85 million in total — is immaterial against the $223 million cash balance as of March 31, 2026.
The more durable consequence is the CIA. The requirement to engage an independent review organization means an outside party will periodically audit EyePoint's federal healthcare program compliance for the next five years — a tangible ongoing obligation even though DEXYCU is no longer sold. For a company that is now entirely clinical-stage and has essentially no product revenues, the practical burden of maintaining the CIA's compliance infrastructure falls on a lean organization already spending roughly $72 million per quarter on research and development alone. The board compliance expert requirement, in particular, adds a governance layer that will persist well past any potential commercialization of DURAVYU.
There is a meaningful counterweight: DEXYCU's commercial program is finished, so the conduct the CIA is designed to prevent is no longer possible in the same form. The CIA's focus on federal healthcare program compliance also becomes less operationally intensive if, as currently planned, EyePoint brings DURAVYU to market through a significantly different commercial model than the sampling-intensive approach alleged for DEXYCU. The government's agreement not to pursue program exclusion — the most severe sanction available — removes the existential risk that had hung over the company since the investigation began.